Skip to main content
Erschienen in: BMC Neurology 1/2020

Open Access 01.12.2020 | Research article

Elevated blood urea nitrogen is associated with recurrence of post-operative chronic subdural hematoma

verfasst von: Ning Wang, Jiangnan Hu, Anthony Oppong-Gyebi, Xuanhao Zhu, Yihao Li, Jianjing Yang, Linhui Ruan, Qichuan Zhuge, Sheng Ye

Erschienen in: BMC Neurology | Ausgabe 1/2020

Abstract

Background

Chronic subdural hematoma (CSDH) is fundamentally treatable with about a 2–31% recurrence rate. Recently, there has been renewed interest in the association between Blood Urea Nitrogen (BUN) and intracranial lesion. Therefore, this paper attempts to show the relationship between BUN and CSDH recurrence.

Methods

A total of 653 CSDH cases with Burr-hole Irrigation (BHI) were enrolled from December 2014 to April 2019. The analyzed parameters included age, gender, comorbidities, laboratory investigations, medication use and hematoma location. The cases were divided into recurrence and non-recurrence groups while postoperative BUN concentration was further separated into quartiles (Q1 ≤ 4.0 mmol/L, 4.0 < Q2 ≤ 4.9 mmol/L, 4.9 < Q3 ≤ 6.4 mmol/L, Q4 > 6.4 mmol/L). Restricted cubic spline regressions and logistic regression models were performed to estimate the effect of BUN on CSDH recurrence.

Results

CSDH recurrence was observed in 96 (14.7%) cases. Significant distinctions were found between recurrence and non-recurrence groups in postoperative BUN quartiles of cases (P = 0.003). After adjusting for the potential confounders, the odds ratio of recurrence was 3.069 (95%CI =1.488–6.330, p = 0.002) for the highest quartile of BUN compared with the lowest quartile. In multiple-adjusted spline regression, a high BUN level visually showed a significantly high OR value of recurrence risk.

Conclusions

Elevated BUN at post-operation is significantly associated with the recurrence of CSDH, and it is indicated that high levels of serum BUN after evacuation may serve as a risk factor for CSDH recurrence.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12883-020-01985-w.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CSDH
Chronic subdural hematoma
BUN
Blood Urea Nitrogen
BHI
Burr-hole irrigation
GCS
Glasgow coma score
CT
Computed tomography
MRI
Magnetic resonance imaging
AIS
Acute ischemic stroke
GOS
Glasgow Outcome Scale
ANOVA
Analysis of variance
OR
Odds ratio
CI
Confidence interval
Cr
Creatinine
PAMBA
Para-aminomethylbenzoic acid
SBP
Systolic blood pressure
DBP
Diastolic blood pressure
INR
International normalized ratio
VEGF
Vascular endothelial growth factor
FDPs
Fibrinogen degradation products

Background

Chronic subdural hematoma (CSDH) is a frequently encountered neurosurgical disorder that is common among the aged. The incidence of CSDH is estimated to be 8.2–17.6 per 100,000 persons per year which increases along with increasing age [13]. Burr-hole irrigation (BHI) is most widely used to treat CSDH with a relatively good outcome, but about 2–31% of patients relapse after the initial operation [1].
Factors found to influence CSDH recurrence have been reported in several studies, including age, Glasgow coma score (GCS), antiplatelet or anticoagulant agents, bilateral hematomas, postoperative pneumocephalus, and other certain related computed tomography (CT) findings [47]. However, the findings of the connection between laboratory investigation and CSDH recurrence are still scarce.
Blood urea nitrogen (BUN) concentration is an easily overlooked investigation. Interestingly, there is a growing amount of literature that recognizes high BUN/creatinine(Cr) as an independent risk factor of poor outcomes in acute ischemic stroke (AIS) patients [810]. Furthermore, elevated BUN concentration was revealed to increase in-hospital mortality in AIS patients [11]. These studies indicated that BUN was associated with intracranial disorders. But very little attention has been paid to the relationship between BUN and CSDH recurrence so far.
In this paper, variables associated with CSDH recurrence were investigated, focusing on the postoperative BUN concentrations of patients with CSDH who underwent evacuation at a single facility from 2014 to 2019. This research aimed to explore the relationship between serum BUN levels and CSDH recurrence to provide a new orientation to study the pathophysiology of CSDH.

Methods

Patients and parameters

This study enrolled admitted patients with the diagnosis of CSDH at the First Affiliated Hospital of Wenzhou Medical University, Zhejiang province, China, between December 2014 and April 2019. Patients with CSDH were diagnosed by head magnetic resonance imaging (MRI) and CT. The following exclusive criteria were used:(1) without surgical treatment;(2) younger than 18 years old;(3) severe epilepsy;(4) severe renal or blood diseases;(5) hematoma organized or bad operation result;(6) craniotomy or evacuated by other departments;(7) lack of laboratory investigation;(8) hospital mortality. Patient with two operations was defined as two cases.
The following clinical characteristics were analyzed: age, gender, demographic parameters, comorbidities, postoperative laboratory investigations, postoperative medication use, location of hematoma, and preoperative BUN level. Glasgow outcome scale (GOS) at discharge was performed to evaluate the neurologic function of patients.

Surgery procedure and follow-up

All patients underwent BHI with general anesthesia. After burr-hole exposure, dura incision and irrigation, we used closed system drainage with a subdural catheter connected to a vacuum plastic bag. Most catheters were withdrawn within 72 h after the operation. Head CT was performed within the first 48 h and on day 6 or 7 postoperatively. For good measure, patients were followed up with head CT at 3 months at the outpatient service.

Definition of recurrence and grouping

CSDH recurrence was evaluated by radiological criteria, which included an increased volume of the subdural collection and brain compression on either side within 3 months compared with those first measured after surgery through CT scans, and clinical criteria in which preoperative symptoms and signs abided or recurred (Fig. 1). The classification of recurrence was determined by two experienced neurosurgeons who were blinded to the study.
The cases were first divided into 2 groups according to recurrence and non-recurrence to investigate the risk factors for CSDH recurrence. To identify the specific effect of postoperative BUN, it was further divided into quartiles to explore the different influences on the CSDH recurrence in each category. The local ethics committee ruled that no formal ethics approval was required in this particular study.

Statistical analysis

Data for continuous variables were shown as mean ± standard deviation or medians and interquartile range. To verify whether the data follows a normal distribution or not, Kolmogorov-Smirnov test was performed. Categorical variables were shown as relative frequencies and percentages. Normally distributed variables were compared by Student’s t-test, whereas the Mann–Whitney U test was used for the asymmetrically distributed continuous variables. Chi-squared (χ2) test was used to compare categorical variables. Statistical comparisons among BUN concentrations stratification were estimated by one-way analysis of variance (ANOVA) or Kruskal–Wallis test for continuous variables, and Pearson’s chi-square test for categorical variables where appropriate. Wilcoxon signed-rank test was performed to compare the difference between pre and post-operative BUN levels. Odds ratio (OR) and 95% confidence interval (CI) for recurrence risk were calculated by performing multivariate-adjusted binary logistic regression. Restricted cubic spline regressions model was built to examine the linear relation between serum BUN concentration and the risk of recurrence. In this study, a two-tailed p-value less than 0.05 (P < 0.05) was considered as statistical significance. All statistical analyses were done using SPSS (version 23.0, IBM Corp.) and STATA software (version 12, StataCorp LP) was employed to analyze the restricted cubic spline regressions.

Results

Baseline characteristics of all cases in the recurrence group and non-recurrence group

A total of 653 CSDH cases were enrolled in this study (Fig. 2). This study group included 561 male cases (85.9%) and 92 female cases (14.1%). Patient’s age ranged from 21 to 100 years with a median of 72 years (interquartile range 64 to 80 years). (Table 1). 8 patients with hospitalized mortality were excluded and there was no mortality upon follow-up in this study.
Table 1
Clinical and Demographic Characteristics of Patients with CSDH
Variables
All patients
(N = 653)
Recurrence(n = 96)
Non-Recurrence(n = 557)
P-value
Postoperative BUN (mmol/L)
4.9 (4,6.4)
5.9 (4.4,6.9)
4.9 (3.9,6.3)
< 0.001
Demographic parameters
 Age (years)
72 (64,80)
75 (69,82)
71 (63,80)
0.012
 Gender
   
0.263
  Male, n (%)
561 (85.9%)
86 (89.6%)
475 (85.3%)
 
  Female, n (%)
92 (14.1%)
10 (10.4%)
82 (14.7%)
 
 Current drinking, n (%)
234 (35.8%)
34 (35.4%)
200 (35.9%)
0.926
 Current smoking, n (%)
237 (36.3%)
33 (34.4%)
204 (36.6%)
0.672
 Baseline SBP (mmHg)
138 (126,153)
135 (124,151)
140 (127,153)
0.122
 Baseline DBP (mmHg)
79 (71,87)
77 (71,84)
79 (71,87)
0.091
Laboratory investigation
 Blood glucose (mmol/L)
5.5 (4.7,6.6)
5.7 (5,6.7)
5.4 (4.7,6.6)
0.265
 Cr (μmol/L)
67 (58,77)
68 (60,80)
66 (57,77)
0.097
 Leukocyte (X10^9/L)
6.94 (5.81,8.43)
6.51 (5.52,7.55)
7.01 (5.85,8.62)
0.010
 Neutrophil (X10^9/L)
4.62 (3.68,6.15)
4.30 (3.51,5.31)
4.70 (3.71,6.26)
0.012
 Lymphocyte (X10^9/L)
1.46 (1.10,1.81)
1.46 (1.17,1.83)
1.47 (1.1,1.81)
0.650
 Erythrocyte (X10^12/L)
4.23 ± 0.51
4.19 ± 0.52
4.24 ± 0.51
0.379
 Hemoglobin (g/L)
132 (120,142)
132 (119,142)
132 (119,140)
0.442
 Platelet (X10^9/L)
211 (172,249)
194 (164,239)
213 (175,251)
0.010
 Prothrombin Time(s)
13.3 (12.8,13.9)
13.4 (12.8,14.0)
13.3 (12.8,13.9)
0.642
 INR
1.02 (0.97,1.08)
1.02 (0.98,1.10)
1.02 (0.97,1.07)
0.719
 Fibrinogen (g/L)
3.61 (3.09,4.28)
3.50 (2.89,4.15)
3.64 (3.15,4.30)
0.046
Comorbidities
 Hypertension, n (%)
252 (38.6%)
40 (41.7%)
212 (38.1%)
0.503
 Diabetes mellitus, n (%)
77 (11.8%)
11 (11.5%)
66 (11.8%)
0.913
 Cardiovascular disease, n (%)
42 (6.4%)
6 (6.3%)
36 (6.5%)
0.937
Medication use
 Atorvastatin therapy, n (%)
478 (73.2%)
74 (77.1%)
404 (72.5%)
0.352
 PAMBA therapy, n (%)
189 (28.9%)
26 (27.1%)
163 (29.3%)
0.663
Hematoma location
   
0.957
 Unilateral left, n (%)
288 (44.1%)
42 (43.8%)
246 (44.2%)
 
 Unilateral right, n (%)
216 (33.1%)
31 (32.3%)
185 (33.2%)
 
 Bilateral, n (%)
149 (22.8%)
23 (24.0%)
126 (22.6%)
 
Postoperative bleeding
136 (20.8%)
22 (22.9%)
114 (20.5%)
0.585
GOS at discharge
   
0.549
 5, n (%)
593 (90.8%)
90 (93.8%)
503 (90.3%)
 
 4, n (%)
48 (7.4%)
5 (5.2%)
43 (7.7%)
 
 3, n (%)
12 (1.8%)
1 (1.0%)
11 (2.0%)
 
Preoperative investigation
N = 632
n = 95
n = 537
 
 BUN (mmol/L)
5.3 (4.4,6.5)
5.9 (4.8,6.9)
5.2 (4.3,6.4)
0.001
NOTE. SBP, systolic blood pressure; DBP, diastolic blood pressure; Cr, creatinine; INR, international normalized ratio; PAMBA, para-aminomethylbenzoic acid; BUN, blood urea nitrogen; GOS, Glasgow Outcome Scale
The descriptive characteristics between groups with and without recurrence are shown in Table 1, including the demographics, laboratory, imaging, medication and comorbidity characteristics. In this study, 96 (14.7%) cases were diagnosed as CSDH recurrence, including 16 patients who needed a second operation. Compared with non-recurrence, the cases in the group of recurrence were older and have lower levels of serum leukocyte, neutrophil and platelet count. However, lower serum fibrinogen concentration was examined in recurrence cases (P < 0.05). Moreover, there was a statistical difference between pre and post-operative groups on serum BUN concentration (P = 0.001 and P < 0.001, respectively). Table 2 revealed that the BUN level of the pre-operative group was significantly higher than the post-operative BUN level in the non-recurrence group (P < 0.001) while it showed no obvious difference in the recurrence group.
Table 2
The comparison between pre- and post-operative BUN levels
Variable
Preoperative BUN (mmol/L)
Postoperative BUN (mmol/L)
P-value
Total (n = 632)
5.3 (4.4,6.5)
4.9 (4.0,6.4)
< 0.001
Recurrence (n = 95)
5.9 (4.8,6.9)
5.85 (4.4,6.9)
0.177
Non-Recurrence (n = 537)
5.2 (44.3,6.4)
4.9 (3.9,6.25)
< 0.001
BUN, blood urea nitrogen;

Baseline characteristics of all cases in BUN quartiles

For further exploration, the cases were divided into 4 groups based on quartiles of the postoperative BUN concentration. The cut-off points for this stratification of the BUN concentration into quartiles were: Q1 ≤ 4.0 mmol/L, 4.0 < Q2 ≤ 4.9 mmol/L, 4.9 < Q3 ≤ 6.4 mmol/L and Q4 > 6.4 mmol/L. Table 3 summarizes the characteristics of the CSDH cases by the quartiles of BUN. Cases with different postoperative BUN concentration appeared to be similar in most features except for age, Cr, erythrocyte and hemoglobin. These factors would be adjusted for multivariate-adjusted binary logistic regression for good measure. 22 (14%) of 157 patients in the highest quartile of BUN suffered moderate disability at discharge which was statistically higher than in other quartiles.
Table 3
Baseline Characteristics of Patients with Chronic Subdural Hematoma according to postoperative BUN quartile
Variables
BUN quartiles
quartile 1 n = 170(≤4.0)
quartile 2 n = 162(> 4.0,≤4.9)
quartile 3 n = 164(> 4.9,≤6.4)
quartile 4 n = 157(> 6.4)
P-value
BUN (mmol/L)
3.4 (3.0,3.7)
4.5 (4.3,4.8)
5.7 (5.3,6.0)
7.4 (6.9,8.3)
< 0.001
Demographic parameters
 Age (years)
68 (61,76)
72 (63,79)
73 (66,82)
76 (69,83)
< 0.001
 Gender, male, n (%)
140 (82.4%)
148 (91.4%)
141 (86.0%)
132 (84.1%)
0.103
 Current drinking, n (%)
61 (35.9%)
62 (38.3%)
58 (35.4%)
53 (33.8%)
0.866
 Current smoking, n (%)
68 (39.4%)
56 (34.6%)
63 (38.4%)
51 (32.5%)
0.526
 Baseline SBP (mmHg)
138.4 ± 19.4
139.3 ± 19.7
141.0 ± 20.6
142.5 ± 21.0
0.274
 Baseline DBP (mmHg)
79 (71,87)
79 (73,86)
77 (72,88)
78 (71,87)
0.984
Laboratory investigation
 Blood glucose (mmol/L)
5.5 (4.8,6.5)
5.6 (4.7,6.6)
5.6 (4.7,6.8)
5.4 (4.5,6.7)
0.818
 Cr (μmol/L)
60 (54,68)
66 (57,75)
69 (60,80)
74 (63,87)
< 0.001
 Leukocyte (X10^9/L)
7.00 (6.14,8.45)
6.97 (5.81,8.62)
6.98 (5.73,8.33)
6.77 (5.55,8.39)
0.677
 Neutrophil (X10^9/L)
4.78 (3.84,6.31)
4.68 (3.76,6.30)
4.52 (3.59,5.92)
4.52 (3.60,5.95)
0.369
 Lymphocyte (X10^9/L)
1.50 (1.10,1.80)
1.40 (1.10,1.71)
1.50 (1.11,1.87)
1.45 (1.10,1.81)
0.518
 Erythrocyte (X10^12/L)
4.30 ± 0.51
4.27 ± 0.50
4.24 ± 0.52
4.12 ± 0.52
0.008
 Hemoglobin (g/L)
133 (120,144)
133 (123,142)
132 (120,144)
130 (116,139)
0.047
 Platelet (X10^9/L)
219 (174,259)
206 (175,250)
203 (175,243)
201 (162,249)
0.183
 Prothrombin Time (s)
13.3 (12.7,13.8)
13.2 (12.9,13.9)
13.4 (12.9,13.9)
13.4 (12.9,14.1)
0.523
 INR
1.02 (0.97,1.07)
1.02 (0.97,1.08)
1.03 (0.97,1.08)
1.03 (0.97,1.10)
0.484
 Fibrinogen (g/L)
3.55 (3.11,4.38)
3.71 (3.10,4.35)
3.61 (2.97,4.18)
3.67 (3.12,4.26)
0.740
Comorbidities
 Hypertension, n (%)
61 (35.9%)
61 (37.7%)
60 (36.6%)
70 (44.6%)
0.355
 Diabetes mellitus, n (%)
18 (10.6%)
18 (11.1%)
17 (10.4%)
24 (15.3%)
0.480
 Cardiovascular disease, n (%)
9 (5.3%)
10 (6.2%)
11 (6.7%)
12 (7.6%)
0.853
Medication use
 Atorvastatin therapy, n (%)
124 (72.9%)
118 (72.8%)
114 (69.5%)
122 (77.7%)
0.427
 PAMBA therapy, n (%)
40 (23.5%)
45 (27.8%)
53 (32.3%)
51 (32.5%)
0.222
Hematoma location
    
0.367
 Unilateral left, n (%)
68 (40.0%)
82 (50.6%)
75 (45.7%)
63 (40.1%)
 
 Unilateral right, n (%)
62 (36.5%)
48 (29.6%)
55 (33.5%)
51 (32.5%)
 
 Bilateral, n (%)
40 (23.5%)
32 (19.8%)
34 (20.7%)
43 (27.4%)
 
GOS at discharge
    
0.042
 5, n (%)
160 (94.1%)
149 (92.0%)
152 (92.7%)
132 (84.1%)
 
 4, n (%)
8 (4.7%)
10 (6.2%)
8 (4.9%)
22 (14%)
 
 3, n (%)
2 (1.2%)
3 (1.9%)
4 (2.4%)
3 (1.9%)
 
NOTE. SBP, systolic blood pressure; DBP, diastolic blood pressure; Cr, creatinine; INR, international normalized ratio; PAMBA, para-aminomethylbenzoic acid; BUN, blood urea nitrogen; GOS, Glasgow Outcome Scale

Association between the BUN concentrations and recurrence

Significant differences were observed between the recurrence and non-recurrence groups in BUN concentration quartiles of cases (P = 0.003). The proportion of cases in the lowest quartile (≤4.0 mmol/L) was dramatically low in the recurrence group (P = 0.027), whilst the proportion of cases in the highest quartile (> 6.4 mmol/L) was significantly high in the recurrence group (P = 0.012) (Table 4).
Table 4
BUN quartiles of patients
Variable
Recurrence (n = 96)
Non-Recurrence (n = 557)
χ2
P-value
BUN (mmol/L)
  
14.308
0.003
 Quartile 1(≤4.0)
14 (14.6%)
156 (28.0%)
4.870
0.027
 Quartile 2(> 4.0,≤4.9)
22 (22.9%)
140 (25.1%)
0.132
0.717
 Quartile 3(> 4.9,≤6.4)
24 (25.0%)
140 (25.1%)
0.000
0.983
 Quartile 4(> 6.4)
36 (37.5%)
121 (21.7%)
6.283
0.012
BUN, blood urea nitrogen;
In Table 5, with all cases taken as a whole, the condition that CSDH recurrence was interpreted as a dependent variable and the lowest quartile was interpreted as the reference was used for postoperative BUN level in the binary logistic regression models. The highest quartile of BUN concentration (> 6.4 mmol/L) was independently estimated as a risk factor of CSDH recurrence with an unadjusted OR of 3.315 (95%CI:1.711–6.423, P < 0.001). After adjusting for the confounders including sex, age, current alcohol drinking, current smoking, comorbidities (hypertension, diabetes mellitus, coronary heart disease), medicine (Atorvastatin and PAMBA), and laboratory investigation (platelet, fibrinogen, leukocyte, erythrocyte, hemoglobin, Cr), the highest quartile of BUN remained significantly and independently associated with CSDH recurrence (model 1: OR = 2.892, 95% CI:1.463–5.717, P = 0.002; model 2: OR = 2.939, 95% CI:1.480–5.836, P = 0.002; model 3: OR = 3.069, 95%CI:1.488–6.330, P = 0.002). There was no multicollinearity between the independent variables in model 3. Furthermore, restricted cubic spline regressions were used to explore the linear relationship between BUN concentration and the risk of CSDH recurrence (Fig. 3). Most importantly, it could be observed visually that the highest quartile had a significantly high OR value.
Table 5
Multivariate adjusted odds ratios for the association between BUN levels and Recurrence
 
Quartile
ORa
95%CI
P-value
Unadjusted
Middle
1.751
0.863–3.554
0.121
Higher
1.910
0.951–3.837
0.069
Highest
3.315
1.711–6.423
< 0.001
Model 1b
Middle
1.590
0.778–3.252
0.204
Higher
1.713
0.842–3.483
0.137
Highest
2.892
1.463–5.717
0.002
Model 2c
Middle
1.612
0.788–3.299
0.191
Higher
1.768
0.866–3.611
0.118
Highest
2.939
1.480–5.836
0.002
Model 3d
Middle
1.612
0.780–3.333
0.197
Higher
1.733
0.837–3.590
0.139
Highest
3.069
1.488–6.330
0.002
OR, odds radio; CI confidence level; Cr, creatinine; Recurrence of postoperative CSDH
a Reference OR (1.000) is the lowest quartile of BUN for Recurrence of CSDH
b Model 1: adjusted for age, sex, current smoking, current alcohol drinking
c Modal 2: adjusted for covariates from Model 1 and further adjusted for medical history (coronary heart disease, diabetes mellitus, hypertension) and medicine (Atorvastatin and PAMBA)
d Modal 3: adjusted for covariates from Model 2 and further adjusted for Platelet, Fibrinogen, Leukocyte, Erythrocyte, Hemoglobin, Cr

Discussion

To the best of our knowledge, this is the first study to investigate the association between BUN concentration and the recurrence of CSDH after evacuation. Our results indicated that high postoperative BUN concentration was related to the prevalence of CSDH recurrence within 3 months after the operation. Our findings hence suggest that the postoperative BUN concentration could be an available risk factor for CSDH recurrence.
BUN is a waste product of protein catabolism which is linked with poor prognosis and mortality in acute or chronic heart failure [12]. In addition, a study of 3355 AIS patients by You et al. observed that higher BUN had a 3.75-fold higher risk of in-hospital mortality [11]. In the present study, we found that patients with a relatively higher level of BUN were more likely to be moderately disabled at discharge. This was consistent with the previous studies that elevated BUN levels during hospitalization was related to a poor outcome. However, little data was found on the relationship between BUN and recurrence of CSDH. In this study, we observed that cases with a higher BUN level presented a trend toward a higher recurrence rate of CSDH. Furthermore, elevated BUN was associated with an enhanced risk of CSDH recurrence and cases with the highest postoperative BUN (> 6.4 mmol/L) seemed to have a 3.069-fold increase in danger of CSDH recurrence after adjusting for the potential confounders. The normal range of BUN level in the research hospital is 2.8–7.2 mmol/L which means the majority of patients presented with BUN level in the normal range. The BUN levels reflected not only the renal function but also other reactions that were mentioned below. In this study, the Cr level did not have an effect on the recurrence of CSDH which means there was no direct association between renal function and CSDH recurrence. The cutoff value of the postoperative BUN level in this study is 6.4 mmol/L and it indicated that the normal range of BUN level for intracranial lesion might be different from the systematic level. Also, elevated preoperative BUN levels showed an association with the recurrence of CSDH after logistic regression (See Supplemental Table, Additional file 1). Comparison between pre and post-operative BUN levels revealed that the BUN in the non-recurrence group significantly decreased after evacuation while it did not occur in the recurrence group, further confirming the relationship between BUN and CSDH recurrence.
The precise mechanisms underlying the association between elevated BUN and CSDH recurrence remained unclear. A potential explanation for this might be that a systemic increase in serum BUN induces intracranial multiple responses, which in turn can produce hematoma expansion and bring out CSDH recurrence. Some studies have revealed that the predictive value of BUN may be induced by its connection with other variables, such as protein intake, protein catabolism, nitrogen production and neurohormonal activation [12, 13]. On the other hand, CSDH was recently suggested to be formed through complex processes including angiogenesis, fibrinolysis and inflammation [14], and the recurrence of CSDH follows the same process as formation. There is strong evidence to show that vascular endothelial growth factor (VEGF) was related to the generation and steady increase of CSDH fluid volume [1517] as well as the risk of CSDH recurrence [18]. Interestingly, Lin et al. observed that VEGF expression was positively correlated with BUN [19]. Hence, these discoveries might explain the relatively good correlation between elevated BUN and CSDH recurrence.
Compared with CSDH cases without recurrence, our result also showed that CSDH cases with recurrence had significantly higher age, which is consistent with the reports of previous studies [7, 20]. However, we found that the older cases were associated with higher BUN and the difference of patient age was not statistically significant after multivariate logistic regression analysis though age affects the recurrence of CSDH through the change of BUN.
Additionally, decreased fibrinogen level was found to be associated with the CSDH recurrence. In fact, fibrinogen has been proven to be a potentially available risk factor for postoperative intracranial bleeding [21, 22] considering that elevating serum fibrinogen was targeted as a valid therapy for intracranial hemorrhage [23]. Moreover, high levels of fibrinogen degradation products (FDPs) have been examined in CSDH fluid [24, 25] and fresh red cells were identified within CSDH fluid [24], suggesting that bleeding is an essential part of CSDH formation. The current study did not reveal a significant difference between postoperative atorvastatin use and CSDH recurrence. This finding runs contrary to existing studies [26, 27], hence, making the relationship between atorvastatin administration and CSDH recurrence puzzling.
There were a few limitations recognized in the present study. First, this study is a retrospective study and the selection bias is inevitable. Secondly, this is only a single-center clinical finding, which may impact the generalization of the results, thus further prospective research with plenty of patients might be required. Finally, considering that the role BUN plays in the CSDH recurrence is still confusing, more studies need to be pursued to further and better delineate CSDH formation in the future.

Conclusion

The most obvious finding from this study was that elevated BUN at post-operation was independently associated with the recurrence of CSDH. The result suggested that a high level of postoperative BUN might serve as a risk factor of CSDH recurrence, so the determination of serum BUN after evacuation is important for patients with CSDH. Further prospective studies need to be undertaken to validate the causal relationship between BUN and CSDH recurrence.

Acknowledgments

Not applicable.
The ethics committee of Wenzhou Medical University First Affiliated Hospital ruled that no formal ethics approval was required in this retrospective study and determined that informed consent was not required.
Not applicable.

Competing interests

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
Metadaten
Titel
Elevated blood urea nitrogen is associated with recurrence of post-operative chronic subdural hematoma
verfasst von
Ning Wang
Jiangnan Hu
Anthony Oppong-Gyebi
Xuanhao Zhu
Yihao Li
Jianjing Yang
Linhui Ruan
Qichuan Zhuge
Sheng Ye
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Neurology / Ausgabe 1/2020
Elektronische ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-01985-w

Weitere Artikel der Ausgabe 1/2020

BMC Neurology 1/2020 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.